The aims were to determine the biodistribution, translocation, and persistence of nanoceria in the brain and selected peripheral organs. Nanoceria is being studied as an anti-oxidant therapeutic. Five, 15, 30, or 55 nm ceria was iv infused into rats which were terminated 1, 20, or 720. h later. Cerium was determined in blood, brain, liver, and spleen. Liver and spleen contained a large percentage of the dose, from which there was no significant clearance over 720. h, associated with adverse changes. Very little nanoceria entered brain parenchyma. The results suggest brain delivery of nanoceria will be a challenge. From the Clinical Editor: This team of investigators revealed that nanoceria, which is being studied as an anti-oxidant, has very limited uptake by the brain regardless of the range of sizes studied, suggesting major challenges in the application of this novel approach in the central nervous system.
|Number of pages||10|
|Journal||Nanomedicine: Nanotechnology, Biology, and Medicine|
|State||Published - Apr 2013|
Bibliographical noteFunding Information:
Sources of support: This work was supported by United States Environmental Protection Agency Science to Achieve Results [grant number RD-833772 ]. Although the research described in this article has been funded wholly or in part by the United States Environmental Protection Agency through STAR Grant RD-833772, it has not been subjected to the Agency's required peer and policy review and therefore does not necessarily reflect the views of the Agency and no official endorsement should be inferred.
ASJC Scopus subject areas
- Medicine (miscellaneous)
- Molecular Medicine
- Biomedical Engineering
- Materials Science (all)
- Pharmaceutical Science